Stacy Blain is the Founder and CEO of Concarlo Therapeutics, which is the first company to target CDK4/6-driven cell proliferation and CDK2-driven resistance

She describes the unmet need for patients who no longer respond to the large CDK4/6 class of medicines, and the decades of work she has put into solving the problem of adding CDK2 inhibition into the equation.